PAR-25-069-Full-Announcement.html

This document is a Request for Application (RFA) for the federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)". The goal of this funding announcement is to promote preclinical and patient-based studies examining the mechanisms through which incretin mimetics (such as agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk. This R01 grant is being offered by the Department of Health and Human Services National Institutes of Health under the Cancer Cause and Prevention Research program (CFDA 93.393). Eligible applicant types include for-profit organizations, non-profit organizations, higher education institutions, small businesses, and state/local governments. The funding amount and award dates are not specified in the announcement. The deadline for submitting applications is not provided.